Latest approval covers use in STEMI patients undergoing percutaneous coronary intervention.

The Medicines Company received pan-EU clearance for the direct thrombin inhibitor, Angiox®, as an anticoagulant in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).

The drug was previously approved in Europe for the treatment of adults with unstable angina/non-STEMI who were to undergo urgent or early intervention. Angiox is designed for use in combination with aspirin and clopidogrel.

The latest EU approval for the STEMI-PCI indication is based on data from a trial that showed Angiox to significantly reduce overall mortality, heart-related deaths, and the incidence of major bleeding in comparison to therapy involving heparin and a platelet glycoprotein IIb/IIIa inhibitor.

In the U.S. the drug is called Angiomax. The Medicines Company reported U.S. Angiomax sales of $194.3 million for the first six months of 2009, up 21% from sales of $161.3 million reported for the first six months of 2008. International net revenues from Angiomax/Angiox were $7.7 million in the first six months this year, compared with $4.2 million in the first six months of 2008.

Previous articleLink Technologies Licenses University of Manchester’s Platform to Reduce Background Fluorescent Signal
Next articleReport Highlights Biotech Strengths, Opportunities, and Weaknesses in Newest EU Countries